Background: Increased research efforts have demonstrated that lncRNAs are associated with multiple head and neck tumors and play important roles in cancer. We previously found that RP11-169D4.1-001 plays a tumor-suppressive role in laryngeal cancer, but its function in human hypopharyngeal squamous cell carcinoma (HSCC) remains unknown. Thus, this research aimed to analyze the relationship between RP11-169D4.1-001 expression and HSCC clinicopathological features. Methods: Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to detect the expression of RP11-169D4.1-001 in 70 pairs of HSCC and adjacent normal tissues.
| INTRODUC TI ON
The long noncoding RNA (lncRNA) described herein, RP11-169D4.1-001, is expressed in eukaryotic cells, exceeds 200 nucleotides in length, and has no protein-coding functions. 1 In recent years, many experiments have proven that lncRNAs play important roles in tumor occurrence and progression. lncRNAs can be used for early tumor diagnosis, prognosis evaluation, and novel treatment, but their specific mechanism of action remains unclear. 2, 3 Hypopharyngeal squamous cell carcinoma (HSCC) accounts for only 3%-5% of all head and neck malignancies, 4 and the annual incidence rates of HSCC are approximately 2 ~ 5/100 000 worldwide and approximately 2 ~ 4/100 000 in China. Among the malignant tumors diagnosed annually worldwide, 2.4% are hypopharyngeal cancer, and the incidence of hypopharyngeal cancer has increased in recent years. 5 Clinically, squamous cell carcinoma is the main type of hypopharyngeal cancer, which has hidden sites of onset and poor biological characteristics and is prone to cervical lymph node metastasis.
Despite advances in surgical and nonsurgical treatment, the overall fraction of hypopharyngeal cancer patients who survive has not been enhanced, and the illness is continually associated with a poor prognosis. In the initial treatment of hypopharyngeal carcinoma, 60%-80% of patients exhibit lymph node metastasis on the same side of the neck, 6 and 40% of patients exhibit contralateral neck lymph node metastasis. 7 The larynx and posterior ring space are easily invadable in the early disease stages, and hypopharyngeal carcinoma is often diagnosed in the late stages, a factor underlying the poor prognosis for head and neck cancer patients. The 5-year survival rate for these patients remains at approximately 40%. 8 Patients with this cancer often exhibit no specific symptoms in the early stages of disease, often reach the late stages of clinical treatment, and thus miss out on valuable treatment opportunities. Furthermore, because the larynx and pharynx play key roles in the functions of pronunciation, breathing, and eating, among other activities, surgical resection treatment will inevitably severely damage the abovementioned functions and greatly reduce the patient's quality of life. 9 Currently, the role of lncRNAs in hypopharyngeal cancer is largely unknown. While how to diagnose hypopharyngeal cancer early and how to preserve these functions during treatment are concerns, specific early diagnostic markers and new treatments that can be applied clinically are lacking, and studying the occurrence and developmental mechanisms of laryngeal and hypopharyngeal cancer can provide a theoretical basis and a new direction for solving this problem. In this study, we further studied the expression of RP11-169D4.1-001 in hypopharyngeal cancer tissue. We aimed to analyze the relationship between RP11-169D4.1-001 expression and clinicopathological features to determine whether this lncRNA can serve as a biomarker of hypopharyngeal cancer. 
| MATERIAL S AND ME THODS

| Patient sample collection
| Total RNA extraction
TRIzol reagent (Invitrogen) was used to extract total RNA from the HSCC and adjacent normal tissue samples, and a NanoDrop spectrophotometer and an Agilent 2100 Bioanalyzer (Agilent Technologies) were used to measure the RNA concentration and purity, respectively.
The amount of RNA was calculated based on 1 OD 260 nm = 40 μg of RNA, and an A260/A280 ratio ranging from 1.8 to 2.1 was used to qualify RNA that could be used in subsequent experiments. 10 
| Quantitative real-time polymerase chain reaction
| Statistical analysis
The data were analyzed with SPSS software 18.0 (SPSS Inc. was significantly lower in the tumor samples compared to that in adjacent noncancerous mucosal samples (P = .001; Figure 1 ).
| RE SULTS
| RP11-169D4.1-001 expression levels in hypopharyngeal carcinoma and adjacent normal tissues
| Relationship between the expression level of RP11-169D4.1-001 and clinicopathological factors in patients with hypopharyngeal carcinoma
As shown in Table 1 expression was associated with T category (P = .008) and lymph node metastasis (P = .001).
| Relationship between RP11-169D4.1-001 expression level and survival time
Kaplan-Meier analysis demonstrated that patients with high RP11-169D4.1-001 expression had a shorter overall survival than patients with low RP11-169D4.1-001 expression ( Figure 2) . A log-rank test confirmed that the results were statistically significant (P < .05). Importantly, multivariate analysis also indicated that RP11-169D4.1-001 was an independent factor for prognosis ( Table 2 ).
The results indicate that the expression of RP11-169D4.1-001 may be involved in the development of HSCC and may affect patient survival.
| Diagnostic efficiency of the target gene
Receiver operating characteristic curves were constructed using paracancerous tissues as controls ( Figure 3 ). The area under the RP11-169D4.1-001 curve was 0.66 (95% CI = 0.568 ~ 0.749, P < .05), the cutoff point was ΔCt = 13.82, and the sensitivity and specificity were 0.54 and 0.7, respectively. a certain accuracy at 0.7 ~ 0.9; and a higher accuracy above 0.9. 12 Through ROC curve analysis, we found that RP11-169D4.1-001 had a lower diagnostic value and lower sensitivity and specificity in HSCC.
| D ISCUSS I ON
Of course, this finding may be due to the limited number of samples studied, and we are not completely sure that RP11-169D4. Head and neck malignancies represent the sixth most common malignancy worldwide, 16 cies is currently receiving increasing attention. 19, 20 We previously found that HOTAIR, NEAT1, AB209630, and other lncRNAs can be used as important prognostic markers for laryngeal carcinomas and play important roles in the multiplication, metastasis, and invasive mechanisms of tumors. [21] [22] [23] However, few studies on lncRNAs associated with hypopharyngeal cancer have been published, and the specific roles of these lncRNAs and the signaling pathways involved are unclear.
Cervical lymph node drainage is abundant, and different primary tumors in the head and neck are prone to cervical lymph node metastasis. Due to the unique lymphatic and vascular anatomy of hypopharyngeal carcinoma, the tumor is prone to cervical lymph nodes and distant metastasis and mainly invades the cervical lymph nodes (II-IV area) and the posterior pharyngeal lymph nodes. [24] [25] [26] [27] Many studies have found that cervical lymph node metastasis is a major factor affecting the prognosis of patients with hypopharyngeal carcinoma. [28] [29] [30] Therefore, the treatment of hypopharyngeal cancer must address the underlying cervical lymph node spread and early primary tumors. In the next study, we can confirm our findings with new patients and relevant preoperative and postoperative blood samples can be collected.
RP11-169D4.1-001 can be found in the Ensembl database
under database number ENST00000450804. The expression and function of RP11-169D4.1-001 in laryngeal carcinoma have been studied. 21 ChIP expression profile analysis showed that RP11-169D4.1-001 was expressed at a 5.26-fold higher level in laryngeal cancer tissue than in normal tissue (P = .002). 21 Shen 21 found the expression of RP11-169D4.1-001 in 88 laryngeal cancerous tissue specimens to be significantly lower than that in adjacent noncancerous tissue samples (P < .001) and to be significantly lower in metastatic lymph nodes than in nonmetastatic lymph nodes (P < .05). In this study, we analyzed the clinical features of 70 patients with hypopharyngeal carcinoma and the expression of RP11-169D4.1-001 in tissue samples from these patients. Previous studies have shown that smoking is a risk factor for upper gastrointestinal cancers, including laryngeal, hypopharyngeal, and esophageal cancers. 31 Therefore, the current study specifically studied the relationship between RP11-169D4.1-001 expression and cigarette smoking, revealing that this association was not statistically significant (P = .437). Thus, we surmise that silencing RP11-169D4.1-001 expression may downregulate the body's tumor suppressor signaling pathway, which promotes the progression of laryngeal and hypopharyngeal cancer, and hypothesize that overexpressing RP11-169D4.1-001 may help inhibit tumor progression. However, whether this lncRNA can be used as an important marker for the follow-up monitoring of patients with hypopharyngeal cancer requires further study. In addition, further exploring the specific role and mechanism of RP11-169D4.1-001 in the development of hypopharyngeal carcinogenesis is still necessary to provide novel diagnostic and treatment strategies for hypopharyngeal cancer.
| CON CLUS ION
High RP11-169D4.1-001 expression is associated with the risk and prognosis of HSCC; therefore, this lncRNA may be a biomarker for assessing HSCC. 
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